PL4146348T3 - Inhibitory kinazy nek7 - Google Patents
Inhibitory kinazy nek7Info
- Publication number
- PL4146348T3 PL4146348T3 PL21770328.9T PL21770328T PL4146348T3 PL 4146348 T3 PL4146348 T3 PL 4146348T3 PL 21770328 T PL21770328 T PL 21770328T PL 4146348 T3 PL4146348 T3 PL 4146348T3
- Authority
- PL
- Poland
- Prior art keywords
- nek7
- kinase
- inhibitors
- nek7 kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063022159P | 2020-05-08 | 2020-05-08 | |
| US202163170761P | 2021-04-05 | 2021-04-05 | |
| PCT/US2021/031394 WO2021242505A1 (en) | 2020-05-08 | 2021-05-07 | Inhibitors of nek7 kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4146348T3 true PL4146348T3 (pl) | 2024-11-12 |
Family
ID=77774963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21770328.9T PL4146348T3 (pl) | 2020-05-08 | 2021-05-07 | Inhibitory kinazy nek7 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11161852B1 (pl) |
| EP (1) | EP4146348B1 (pl) |
| JP (2) | JP7796671B2 (pl) |
| KR (1) | KR20230008763A (pl) |
| CN (2) | CN115843272B (pl) |
| AU (1) | AU2021280893A1 (pl) |
| BR (1) | BR112022022669A2 (pl) |
| CA (1) | CA3182276A1 (pl) |
| CO (1) | CO2022017622A2 (pl) |
| DK (1) | DK4146348T3 (pl) |
| ES (1) | ES2991366T3 (pl) |
| FI (1) | FI4146348T3 (pl) |
| HR (1) | HRP20241304T1 (pl) |
| HU (1) | HUE068185T2 (pl) |
| IL (1) | IL297979A (pl) |
| LT (1) | LT4146348T (pl) |
| MX (1) | MX2022013984A (pl) |
| PH (1) | PH12022553024A1 (pl) |
| PL (1) | PL4146348T3 (pl) |
| PT (1) | PT4146348T (pl) |
| RS (1) | RS65962B1 (pl) |
| SI (1) | SI4146348T1 (pl) |
| TW (1) | TWI923584B (pl) |
| WO (1) | WO2021242505A1 (pl) |
| ZA (1) | ZA202212146B (pl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3182276A1 (en) * | 2020-05-08 | 2021-12-02 | Halia Therapeutics, Inc. | Inhibitors of nek7 kinase |
| CN114751874B (zh) * | 2022-05-30 | 2025-01-24 | 江南大学 | 作为TRPV4-KCa2.3促耦联剂的1-苄基-4-乙基哌嗪衍生物及其应用 |
| AR130318A1 (es) | 2022-08-29 | 2024-11-27 | Japan Tobacco Inc | Compuestos de pirazolopirimidina y su uso médico |
| WO2024059200A1 (en) * | 2022-09-14 | 2024-03-21 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| WO2024167423A1 (en) | 2023-02-07 | 2024-08-15 | Captor Therapeutics S.A. | Gspt1 degrader compounds |
| AU2024282230A1 (en) * | 2023-05-26 | 2025-12-04 | Halia Therapeutics, Inc. | Polymorphs of nek 7 inhibitors |
| TW202517271A (zh) * | 2023-07-06 | 2025-05-01 | 美商哈利亞製藥公司 | Nek7激酶抑制劑之醫藥組合物 |
| WO2025067411A1 (zh) * | 2023-09-28 | 2025-04-03 | 北京普祺医药科技股份有限公司 | 一种nek7抑制剂、药物组合物及其用途 |
| CN122535593A (zh) * | 2023-12-29 | 2026-08-07 | 北京普祺医药科技股份有限公司 | 一种nek7抑制剂、药物组合物及其用途 |
| WO2025160453A1 (en) * | 2024-01-25 | 2025-07-31 | Halia Therapeutics, Inc. | Heterocyclic compounds, such as ht-6184, for use in the treatment of pain |
| WO2025190317A1 (en) * | 2024-03-13 | 2025-09-18 | National Institute Of Biological Sciences, Beijing | Urea compounds as nlrp3 agonists |
| CN118812538A (zh) * | 2024-06-18 | 2024-10-22 | 南京健康产业研究院 | 一种具有抗肾癌活性的化合物及其制备方法与应用 |
| WO2026162580A1 (en) * | 2025-01-29 | 2026-08-06 | Monte Rosa Therapeutics Ag | Combinations comprising nek7-targeting degraders |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| AU2000240570A1 (en) | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
| KR100600550B1 (ko) | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| TWI263640B (en) | 2001-12-19 | 2006-10-11 | Bristol Myers Squibb Co | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| GB0225579D0 (en) | 2002-11-02 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
| WO2005048953A2 (en) | 2003-11-13 | 2005-06-02 | Ambit Biosciences Corporation | Amide derivatives as kinase modulators |
| AU2006223409B2 (en) | 2005-03-10 | 2011-07-21 | Gilead Connecticut, Inc. | Certain substituted amides, method of making, and method of use thereof |
| KR20100042287A (ko) | 2007-07-31 | 2010-04-23 | 쉐링 코포레이션 | 항암요법으로서의 항-유사분열제 및 아우로라 키나제 억제제 조합물 |
| AU2009226136B2 (en) | 2008-03-17 | 2013-08-15 | Ambit Biosciences Corporation | Quinazoline derivatives as RAF kinase modulators and methods of use thereof |
| CA2737645A1 (en) | 2008-09-25 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the cb2 receptor |
| EP2348018A4 (en) | 2008-09-25 | 2012-04-25 | Kyorin Seiyaku Kk | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR CONTAINING ACTIVE SUBSTANCE |
| KR20120059558A (ko) | 2009-08-19 | 2012-06-08 | 암비트 바이오사이언시즈 코포레이션 | 바이아릴 화합물 및 이의 사용 방법 |
| CA2795952A1 (en) | 2010-04-16 | 2011-10-20 | Curis, Inc. | Treatment of cancers having k-ras mutations |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| BR112014017209A8 (pt) | 2012-01-12 | 2017-07-04 | Basf Se | compostos, composição, método para a preparação de uma composição e método para o controle da vegetação indesejável |
| CN105431436B (zh) | 2013-05-14 | 2017-11-28 | 内尔维阿诺医学科学有限公司 | 吡咯并[2,3‑d]嘧啶衍生物，它们的制备方法和它们作为激酶抑制剂的用途 |
| AU2014278231B2 (en) | 2013-06-11 | 2017-05-25 | KALA BIO, Inc. | Urea derivatives and uses thereof |
| WO2014206343A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
| US9290519B2 (en) | 2013-11-15 | 2016-03-22 | Exxonmobil Chemical Patents Inc. | Pyridyldiamido transition metal complexes, production and use thereof |
| EP3218378B1 (en) | 2014-11-14 | 2020-01-08 | Nerviano Medical Sciences S.r.l. | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors |
| US10688077B2 (en) | 2015-02-26 | 2020-06-23 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inflammasome activation in myelodysplastic syndromes |
| CN106220644B (zh) | 2015-04-24 | 2020-07-31 | 广州再极医药科技有限公司 | 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用 |
| PL3359541T3 (pl) | 2015-10-09 | 2021-01-11 | AbbVie Overseas S.à r.l. | N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA |
| HRP20200133T1 (hr) | 2016-01-22 | 2020-05-15 | Janssen Pharmaceutica Nv | Novi supstituirani derivati cijanoindolina kao inhibitori nik |
| CN107176951A (zh) | 2016-03-11 | 2017-09-19 | 恩瑞生物医药科技（上海）有限公司 | 一种脲类化合物、其制备方法及其医药用途 |
| US10167703B2 (en) | 2016-03-31 | 2019-01-01 | Saudi Arabian Oil Company | Optimal well placement under constraints |
| KR102500416B1 (ko) | 2016-06-21 | 2023-02-17 | 네르비아노 메디칼 사이언시스 에스.알.엘. | 키나제 억제제로서의 n-(치환된-페닐)-설폰아미드 유도체 |
| CN109789135A (zh) | 2016-07-20 | 2019-05-21 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为perk抑制剂的异喹啉衍生物 |
| EP3296297A1 (en) | 2016-09-15 | 2018-03-21 | Centre National De La Recherche Scientifique | Benzimidazol derivatives for treating filovirus infection |
| WO2018215668A1 (en) | 2017-05-26 | 2018-11-29 | Glenmark Pharmaceuticals S.A. | Novel inhibitors of map4k1 |
| WO2018228925A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| EP3638669A1 (en) | 2017-06-13 | 2020-04-22 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| US20210324067A9 (en) | 2018-03-09 | 2021-10-21 | The Brigham And Women's Hospital, Inc. | Combination therapy for cardiovascular diseases |
| EP3774797B1 (en) | 2018-04-05 | 2025-11-19 | Merck Patent GmbH | Heteroaryl compounds as type ii irak inhibitors and uses hereof |
| JP2021529780A (ja) | 2018-07-03 | 2021-11-04 | ノバルティス アーゲー | Ｎｌｒｐ３アンタゴニストを使用するｔｎｆ阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法 |
| WO2020035495A1 (en) | 2018-08-14 | 2020-02-20 | Cynora Gmbh | Organic molecules for optoelectronic devices |
| JP2021536458A (ja) | 2018-09-04 | 2021-12-27 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | アリール炭化水素レセプター・アンタゴニスト及び使用方法 |
| GB201815045D0 (en) | 2018-09-14 | 2018-10-31 | Univ Ulster | Bispecific antibody targeting IL-1R1 and NLPR3 |
| JP7619951B2 (ja) | 2018-10-15 | 2025-01-22 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
| DK3886852T3 (da) | 2018-12-03 | 2024-04-29 | Smilebiotek Zhuhai Ltd | Octylgallat og estere deraf til anvendelse ved behandling og forebyggelse af aldersrelateret makuladegeneration forårsaget af bacillus megaterium |
| WO2020139748A1 (en) | 2018-12-28 | 2020-07-02 | Cedars-Sinai Medical Center | Methods of treating inflammatory bowel diseases that target ripk2 |
| WO2020144378A1 (en) | 2019-01-11 | 2020-07-16 | Universitätsspital Basel | Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery |
| ES3034157T3 (en) | 2019-01-29 | 2025-08-13 | Univ Degli Studi Di Salerno | Modulators of potassium ion channels and uses thereof |
| CN111646995B (zh) | 2019-03-04 | 2023-03-21 | 四川大学 | 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途 |
| GB201905265D0 (en) | 2019-04-12 | 2019-05-29 | Inflazome Ltd | Inflammasome inhibition |
| US11559536B2 (en) | 2019-05-20 | 2023-01-24 | Duke University | Compositions and methods for the treatment of inflammation in urological pathology |
| KR20220066290A (ko) | 2019-08-29 | 2022-05-24 | 히버셀, 인크. | Perk 억제 피롤로피리미딘 화합물 |
| CN112552302B (zh) | 2019-09-26 | 2022-05-13 | 深圳市塔吉瑞生物医药有限公司 | 取代的芳香稠合环衍生物及其组合物及用途 |
| US20230140941A1 (en) | 2020-03-13 | 2023-05-11 | University Of Maryland, Baltimore | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors |
| AU2020436612A1 (en) | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
| WO2021188837A1 (en) | 2020-03-20 | 2021-09-23 | The Johns Hopkins University | Prophylaxis and treatment of pathogenic coronavirus infections |
| US20230210853A1 (en) | 2020-05-08 | 2023-07-06 | Halia Therapeutics, Inc. | Targeted nek7 inhibition for modulation of the nlrp3 inflammasome |
| CA3182276A1 (en) * | 2020-05-08 | 2021-12-02 | Halia Therapeutics, Inc. | Inhibitors of nek7 kinase |
| WO2021244582A1 (zh) | 2020-06-02 | 2021-12-09 | 成都康弘药业集团股份有限公司 | 新型甲状腺激素β受体激动剂 |
| AU2021289345A1 (en) | 2020-06-08 | 2023-01-19 | Halia Therapeutics, Inc. | Inhibitors of NEK7 kinase |
| GB202010464D0 (en) | 2020-07-08 | 2020-08-19 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| EP4232020A4 (en) | 2020-10-21 | 2024-08-07 | Kura Oncology, Inc. | Treatment of hematological malignancies with inhibitors of menin |
| US20240400551A1 (en) | 2021-01-25 | 2024-12-05 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| WO2022192944A1 (en) | 2021-03-15 | 2022-09-22 | Genieus Genomics Pty Ltd | Combination therapy for treatment of als |
| JP2024513227A (ja) | 2021-04-05 | 2024-03-22 | ハリア・セラピューティクス・インコーポレイテッド | Ｎｅｋ７阻害剤 |
| WO2022226349A1 (en) | 2021-04-22 | 2022-10-27 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| EP4330228A4 (en) | 2021-04-26 | 2025-03-26 | The Regents of the University of California | G-ALPHA-S INHIBITORS AND USES THEREOF |
| US20240287081A1 (en) | 2021-06-09 | 2024-08-29 | Icahn School Of Medicine At Mount Sinai | Perfluoroalkane substituted pyrazolo[3,4-d]pyrimidin and pyrrolo[2,3-d]pyrimidin compounds and uses thereof |
| CN115616216B (zh) | 2021-07-15 | 2025-08-12 | 华南理工大学 | 抑制或阻断faah与nlrp3之间相互作用的制剂的用途 |
| CN117693340A (zh) | 2021-07-23 | 2024-03-12 | 诺华股份有限公司 | Nlrp3抑制剂治疗骨关节炎的给药方案 |
| TW202333693A (zh) | 2021-12-31 | 2023-09-01 | 大陸商上海翰森生物醫藥科技有限公司 | 苯并哌啶衍生物調節劑、其製備方法和應用 |
-
2021
- 2021-05-07 CA CA3182276A patent/CA3182276A1/en active Pending
- 2021-05-07 TW TW110116590A patent/TWI923584B/zh active
- 2021-05-07 SI SI202130195T patent/SI4146348T1/sl unknown
- 2021-05-07 DK DK21770328.9T patent/DK4146348T3/da active
- 2021-05-07 HR HRP20241304TT patent/HRP20241304T1/hr unknown
- 2021-05-07 MX MX2022013984A patent/MX2022013984A/es unknown
- 2021-05-07 BR BR112022022669A patent/BR112022022669A2/pt unknown
- 2021-05-07 PL PL21770328.9T patent/PL4146348T3/pl unknown
- 2021-05-07 KR KR1020227041803A patent/KR20230008763A/ko active Pending
- 2021-05-07 CN CN202180048858.3A patent/CN115843272B/zh active Active
- 2021-05-07 CN CN202510888448.XA patent/CN120699028A/zh active Pending
- 2021-05-07 WO PCT/US2021/031394 patent/WO2021242505A1/en not_active Ceased
- 2021-05-07 HU HUE21770328A patent/HUE068185T2/hu unknown
- 2021-05-07 ES ES21770328T patent/ES2991366T3/es active Active
- 2021-05-07 PH PH1/2022/553024A patent/PH12022553024A1/en unknown
- 2021-05-07 IL IL297979A patent/IL297979A/en unknown
- 2021-05-07 EP EP21770328.9A patent/EP4146348B1/en active Active
- 2021-05-07 RS RS20241030A patent/RS65962B1/sr unknown
- 2021-05-07 LT LTEPPCT/US2021/031394T patent/LT4146348T/lt unknown
- 2021-05-07 AU AU2021280893A patent/AU2021280893A1/en active Pending
- 2021-05-07 FI FIEP21770328.9T patent/FI4146348T3/fi active
- 2021-05-07 US US17/315,209 patent/US11161852B1/en active Active
- 2021-05-07 PT PT217703289T patent/PT4146348T/pt unknown
- 2021-05-07 JP JP2022567839A patent/JP7796671B2/ja active Active
- 2021-09-14 US US17/475,220 patent/US11713321B2/en active Active
-
2022
- 2022-11-07 ZA ZA2022/12146A patent/ZA202212146B/en unknown
- 2022-12-06 CO CONC2022/0017622A patent/CO2022017622A2/es unknown
-
2023
- 2023-05-23 US US18/322,380 patent/US12091413B2/en active Active
-
2025
- 2025-12-23 JP JP2025278930A patent/JP2026067870A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202212146B (en) | Inhibitors of nek7 kinase | |
| IL308193A (en) | RAS inhibitors | |
| GB202001344D0 (en) | Ras Inhibitors | |
| GB2594788B (en) | Antagonist of PCSK9 | |
| IL320739A (en) | rock2 inhibitors | |
| IL288387A (en) | Small molecule inhibitors of nf-kb factor kinase | |
| IL313548A (en) | MET kinase inhibitors | |
| PT3897833T (pt) | Inibidores de apol1 e métodos de utilização dos mesmos | |
| IL316616A (en) | ROCK2 inhibitors | |
| HUE068818T2 (hu) | Transzglutamináz inhibitorok | |
| HUE068724T2 (hu) | Transzglutaminázok inhibitorai | |
| IL325596A (en) | Pharmaceutical preparations for NEK7 kinase inhibitors | |
| EP3999064A4 (en) | Inhibitors of tyrosine kinase | |
| IL309077A (en) | Transglutaminase inhibitors | |
| SG10201909596RA (en) | Synthesis of Tyrosine Kinase Inhibitors | |
| IL308513A (en) | ALK2 kinase inhibitors containing imidazoles | |
| HK40088585A (en) | Inhibitors of nek7 kinase | |
| ES3065589T3 (en) | Tyrosine kinase inhibitors | |
| GB202107612D0 (en) | Inhibitors of metallo-beta-lactamases | |
| GB202203181D0 (en) | Inhibitors of elF4A | |
| PT4192813T (pt) | Inibidores de transglutaminases | |
| HK40118888A (en) | Inhibitors of met kinase | |
| GB202113104D0 (en) | Antagonist of pcsk9 | |
| GB202020553D0 (en) | Antagonist of pcsk9 | |
| IL326145A (en) | CDK2/4/6 kinase inhibitors |